ArticleFrontiers in oncology2025
Clinicopathological characteristics and clinical outcomes of remnant gastric cancer with endoscopic submucosal dissection.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remnant gastric cancer is distinct from primary gastric cancer clinically and pathologically. Recently, endoscopic submucosal dissection, widely used for treating early gastric cancer, has also been used to treat remnant gastric cancer. However, owing to the previous surgeries, endoscopic resection of remnant gastric cancer is more complicated. This study aimed to elucidate the clinicopathological characteristics of remnant gastric cancer and evaluate clinical outcomes of endoscopic submucosal dissection for this condition. Methods: This retrospective study examined the clinicopathological characteristics and clinical outcomes in 30 patients (32 lesions) with remnant gastric cancer who underwent endoscopic submucosal dissection from 2012 to 2023 at the Endoscopy Center of Peking University Cancer Hospital, China. Results: The primary disease was a malignant tumor in 25 patients and a benign tumor in 4. Billroth II was the major reconstruction method used in the initial surgery. The median interval from previous surgery to remnant gastric cancer detection was 4.2 years. The mean endoscopic submucosal dissection time was 136 ± 71 min. The Conclusions: Remnant gastric cancer development is influenced by the type of initial disease and prior surgery. Endoscopic submucosal dissection is a safe and effective treatment for early remnant gastric cancer, with potential applicability for certain non-early-stage lesions. However, being technically challenging, endoscopic submucosal dissection requires the skills of experienced endoscopists and careful evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.